Richards, Merrill & Peterson, Inc. Voyager Therapeutics, Inc. Transaction History
Richards, Merrill & Peterson, Inc.
- $191 Billion
- Q4 2024
A detailed history of Richards, Merrill & Peterson, Inc. transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Richards, Merrill & Peterson, Inc. holds 30 shares of VYGR stock, worth $126. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30Holding current value
$126% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VYGR
# of Institutions
132Shares Held
35.1MCall Options Held
5.6KPut Options Held
46.2K-
Armistice Capital, LLC New York, NY5.4MShares$22.8 Million0.43% of portfolio
-
Black Rock Inc. New York, NY5.31MShares$22.5 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.92MShares$16.6 Million1.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.22MShares$13.6 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.57MShares$10.9 Million0.08% of portfolio
About Voyager Therapeutics, Inc.
- Ticker VYGR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,647,600
- Market Cap $163M
- Description
- Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...